National Investment Services of America LLC decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 33.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,715 shares of the company’s stock after selling 14,241 shares during the quarter. National Investment Services of America LLC’s holdings in Elanco Animal Health were worth $850,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in shares of Elanco Animal Health by 3.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,468,341 shares of the company’s stock worth $31,497,000 after purchasing an additional 47,779 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in Elanco Animal Health during the 2nd quarter worth approximately $1,208,000. FMR LLC boosted its position in Elanco Animal Health by 33.4% during the 2nd quarter. FMR LLC now owns 1,147,769 shares of the company’s stock worth $24,619,000 after acquiring an additional 287,193 shares during the last quarter. Gabelli Funds LLC boosted its position in Elanco Animal Health by 1.2% during the 2nd quarter. Gabelli Funds LLC now owns 57,600 shares of the company’s stock worth $1,236,000 after acquiring an additional 700 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its position in Elanco Animal Health by 3.3% during the 2nd quarter. Baird Financial Group Inc. now owns 38,942 shares of the company’s stock worth $1,147,000 after acquiring an additional 1,231 shares during the last quarter. 75.86% of the stock is currently owned by institutional investors.
ELAN traded up $0.29 during trading hours on Friday, reaching $31.38. The company’s stock had a trading volume of 2,303,298 shares, compared to its average volume of 2,300,040. Elanco Animal Health Incorporated has a 52 week low of $15.17 and a 52 week high of $34.09. The company’s 50-day moving average is $30.12 and its 200-day moving average is $27.67. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.90 and a current ratio of 1.75. The firm has a market cap of $14.81 billion, a PE ratio of -55.05, a price-to-earnings-growth ratio of 8.32 and a beta of 0.86.
Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a positive return on equity of 3.43% and a negative net margin of 8.45%. The business had revenue of $889.60 million for the quarter, compared to analysts’ expectations of $922.48 million. During the same quarter in the prior year, the business earned $0.30 EPS. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.44 earnings per share for the current fiscal year.
A number of equities analysts have weighed in on the company. Raymond James reaffirmed a “hold” rating on shares of Elanco Animal Health in a research report on Wednesday, October 7th. Argus downgraded Elanco Animal Health from a “buy” rating to a “hold” rating in a research report on Wednesday, December 9th. Morgan Stanley increased their price objective on Elanco Animal Health from $31.00 to $41.00 and gave the company an “overweight” rating in a report on Monday, November 23rd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price objective on Elanco Animal Health from $32.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, November 17th. Finally, TheStreet downgraded Elanco Animal Health from a “c” rating to a “d” rating in a report on Friday, November 6th. Three analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. Elanco Animal Health presently has a consensus rating of “Hold” and an average target price of $29.28.
In related news, major shareholder Aktiengesellschaft Bayer sold 54,500,000 shares of the stock in a transaction on Thursday, December 3rd. The stock was sold at an average price of $29.84, for a total value of $1,626,280,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.12% of the stock is currently owned by corporate insiders.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for companion and food animals. It offers companion animal disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production.
Recommended Story: Inverted Yield Curve
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.